Noul Co., Ltd. (CEO Chan-Yang Lim, hereinafter referred to as Noul) , an AI-based blood and cancer diagnosis specialist, has been selected as a global Top 30 finalist at the 2025 WIPO Global Awards hosted by the World Intellectual Property Organization (WIPO) as a leading Korean company in the healthcare field.
The WIPO Global Awards celebrate the achievements and contributions of startups and small and medium-sized enterprises (SMEs) that leverage intellectual property (IP) to drive business growth and create social impact. This year, a record 780 applications were received from 95 countries, of which 30 companies were selected as finalists by the WIPO Secretariat.
Noul CEO Chan-Yang Lim said, "I am deeply honored that Noul has been selected as a WIPO Global Awards Top 30 finalist. This award recognizes Noul's business efforts, grounded in innovative technology and a systematic intellectual property strategy. I am proud to represent Korea and stand shoulder to shoulder with these global innovative companies."
The WIPO Global Awards Top 30 finalists were selected based on the company's business model and IP portfolio fit, global IP strategy, internal IP culture, and positive social impact. Noul's unique approach and intellectual property strategy in the field of digital healthcare diagnostics led to the development and commercialization of the "milab™ Platform," an innovative diagnostic solution that improves global diagnostic accessibility and accelerates the conquest of cancer.
Marcelo Di Pietro, Director of the WIPO Awards Program, congratulated Noul on his award, saying, "This year's Top 30 finalists exemplify the power of intellectual property. These companies are combining creativity and IP rights to create tangible benefits for business and the world."
Noul develops and markets MyLab, a field diagnostic solution that combines bio-medical engineering and artificial intelligence (AI) for regions and countries with limited access to healthcare. MyLab is a rapid point-of-care diagnostic platform capable of malaria diagnosis, blood analysis, and cervical cytology, eliminating the need for sample transport to a central laboratory and providing high usability. Leveraging its robust IP portfolio, including machine learning, mechanical design, and blood and cell staining technologies, Noul is committed to improving diagnostic accessibility even in underserved areas.
The 2025 WIPO Global Awards Top 30 finalists can be found on the WIPO website , and the final winners will be announced at an awards ceremony during the 66th WIPO General Assembly in Geneva, Switzerland, on July 11.
- See more related articles
You must be logged in to post a comment.